scPharmaceuticals Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" scPharmaceuticals stock.
View analyst ratings for scPharmaceuticals or view top-rated stocks.

Wall Street analysts have given scPharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but scPharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

scPharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for scPharmaceuticals.

scPharmaceuticals Inc. (NASDAQ:SCPH) issued its quarterly earnings data on Wednesday, May, 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04.
View scPharmaceuticals' earnings history.

scPharmaceuticals' stock was trading at $7.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SCPH stock has decreased by 26.4% and is now trading at $5.72.
View which stocks have been most impacted by COVID-19.

2 analysts have issued 12 month price targets for scPharmaceuticals' stock. Their forecasts range from $10.00 to $12.00. On average, they anticipate scPharmaceuticals' stock price to reach $11.00 in the next year. This suggests a possible upside of 92.3% from the stock's current price.
View analysts' price targets for scPharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to scPharmaceuticals include ZIOPHARM Oncology (ZIOP), Inventiva (IVA), Clovis Oncology (CLVS), Applied Therapeutics (APLT), Bolt Biotherapeutics (BOLT), Catalyst Pharmaceuticals (CPRX), Adagene (ADAG), Akebia Therapeutics (AKBA), IVERIC bio (ISEE), Magenta Therapeutics (MGTA), Selecta Biosciences (SELB), AC Immune (ACIU), Altimmune (ALT), Forte Biosciences (FBRX) and BELLUS Health (BLUSF).
View all of SCPH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other scPharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), ImmunoGen (IMGN), VBI Vaccines (VBIV), Selecta Biosciences (SELB), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

(SCPH) raised $96 million in an IPO on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

scPharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

scPharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.98%), Ikarian Capital LLC (4.78%), Goldman Sachs Group Inc. (2.37%), BlackRock Inc. (1.20%), Worth Venture Partners LLC (0.78%) and Renaissance Technologies LLC (0.70%). Company insiders that own scPharmaceuticals stock include Andrew J Schwab, John H Tucker and Ra Capital Management, LP.
View institutional ownership trends for scPharmaceuticals.

SCPH stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Ikarian Capital LLC, Renaissance Technologies LLC, and Northern Trust Corp.
View insider buying and selling activity for scPharmaceuticals or view top insider-selling stocks.

SCPH stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Worth Venture Partners LLC, Morgan Stanley, BlackRock Inc., Geode Capital Management LLC, and Barclays PLC. Company insiders that have bought scPharmaceuticals stock in the last two years include Andrew J Schwab, John H Tucker, and Ra Capital Management, LP.
View insider buying and selling activity for scPharmaceuticals or or view top insider-buying stocks.

Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SCPH stock can currently be purchased for approximately $5.72.

scPharmaceuticals has a market capitalization of $156.47 million. The company earns $-32,210,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis.

scPharmaceuticals employs 27 workers across the globe.

The official website for scPharmaceuticals is www.scpharma.com.

scPharmaceuticals is headquartered at 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830.

scPharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected]